Allergy Therapeuti (NASDAQ:AGYTF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “

Allergy Therapeuti (NASDAQ:AGYTF) opened at 0.39 on Wednesday. The firm has a 50-day moving average price of $0.39 and a 200 day moving average price of $0.39. Allergy Therapeuti has a 1-year low of $0.39 and a 1-year high of $0.39. The stock’s market cap is $231.44 million.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/01/allergy-therapeuti-agytf-stock-rating-upgraded-by-zacks-investment-research.html.

Receive News & Stock Ratings for Allergy Therapeuti Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeuti and related stocks with our FREE daily email newsletter.